Cargando…

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become one of the standard treatment options for advanced lung cancer. However, adverse events (AEs), particularly immune–related AEs (irAEs), caused by these drugs have aroused public attention. The current network meta-analysis (NMA) aimed to co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Yi-Dan, Cui, Jiu-Jie, Fu, Jie, Su, Ying-Jie, Chen, Xiao-Yu, Gu, Zhi-Chun, Lin, Hou-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677695/ https://www.ncbi.nlm.nih.gov/pubmed/34925331 http://dx.doi.org/10.3389/fimmu.2021.760737

Ejemplares similares

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy
por: Zhou, Jiebai, et al.
Publicado: (2023)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023)

Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
por: Gibellini, Lara, et al.
Publicado: (2020)

Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhou, Juyue, et al.
Publicado: (2023)

A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors
por: Zhu, Sihui, et al.
Publicado: (2021)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
por: Zhang, Qi-jie, et al.
Publicado: (2021)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023)

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
por: Jin, Peng, et al.
Publicado: (2022)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia
por: Wang, Shuwen, et al.
Publicado: (2021)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
por: Zhao, Zhe, et al.
Publicado: (2023)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials
por: Liu, Han, et al.
Publicado: (2023)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review
por: Xie, Wang, et al.
Publicado: (2021)

Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review
por: Li, Jun, et al.
Publicado: (2023)

Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
por: Wei, Fuqun, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kgr82lgdqdfm58723567n36tmt